Implications of the FRISCII trial: initial medical stabilization followed by an early invasive approach is the preferred strategy in unstable coronary syndromes.
Wallentin
L
L
Department of Cardiology, University Hospital, Uppsala, Sweden. Lars.Wallentin@card.uas.lul.se
D000789:Angina, Unstable / Q000628:therapy*; D017985:Dalteparin / Q000008:administration & dosage; D004562:Electrocardiography; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D009203:Myocardial Infarction / Q000517:prevention & control; D009204:Myocardial Revascularization; D016032:Randomized Controlled Trials as Topic; D013577:Syndrome; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D017985:Dalteparin